Sandoz Group (OTC:SDZNY) Stock, Quote.Headers.trade-ideas

Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as the first US biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in its pipeline.

biotech shutter

Biotech

News

Health Care

Movers

Trading Ideas

General

CHRS

SDZNY

SDZXF

Coherus sells Udenyca franchise for up to $558.4 million, shifts focus to immuno-oncology R&amp;D, and plans clinical trials in hepatocellular carcinoma and NSCLC.

Why Is Coherus BioSciences Stock Trading Higher On Tuesday?

Screenshot 2024-10-01 at 5.30.51 PM

Cannabis

Psilocybin&#39;s Potentially Revolutionary Ability To Treat Depression Hinges On FDA Approval – AJNA BioSciences Is Standardizing Raw Materials To Meet Guidelines

Konskie,,Poland,-,January,05,,2019:,Unitedhealth,Group,Logo,Displayed

Equities

Large Cap

Media

ABBV

ALVO

AMGN

TEVA

UnitedHealth will remove AbbVie&#39;s Humira from its preferred drug lists by 2025, opting for lower-cost biosimilars like Amgen&#39;s Amjevita, in a move aimed at cutting prescription costs.

UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars

Sandoz Group AG

Asset Sales

COIN

Frederick Ernest Ehrsam III Reported A 2.87% Passive Stake In Coinbase Global As Of Dec 31, 2024 Vs 7.57% On Sept 30, 2024

NARI

Stryker Commences Tender Offer For All Outstanding Shares Of Common Stock Of Inari Medical For $80/Share In Cash

Legal

Spirit Faces Multiple Lawsuits Alleging Omission of Material Information in Merger Proxy; Actions Filed Across New York, Kansas, and Delaware Courts Seeking Injunctive Relief; Spirit Supplements Disclosures to Moot Claims, Denies Allegations

Offerings

Jackson Financial Inc Files For Mixed Shelf; Size Not Disclosed

Analysts turn their focus to the 2025 movie season, offering box office predictions as the industry grapples with the continued <a href="https://www.benzinga.com/topic/streaming">rise of streaming platforms.</a>
JPMorgan 2025 Outlook: The movie theater industry <a href="https://www.benzinga.com/general/entertainment/24/12/42750888/top-anticipated-2025-movies-for-big-screen-success-and-stocks-investors-should-watch">could be normalizing</a> after facing the COVID-19 pandemic disruption and labor stoppages, JPMorgan analyst David Karnovsky said in a new investor note.
"The key headwind for theaters remains supply – COVID and strike-related production shutdowns hampered output, and while the impacts are yet to be fully overcome, the lack of ongoing constraints sets up the conditions for a full recovery in volume by 2026 or 2027," Karnovsky said.
The analyst forecasts the North American box office to hit $9.50 billion in 2025, up 10.8% year-over-year. Broken down by quarter, Karnovsky's predictions are as follows:
<ul>
<li>Q1: $1.77 billion, +9.7% year-over-year</li>
<li>Q2: $2.44 billion, +25.1% year-over-year</li>
<li>Q3: $2.57 billion, -3.7% year-over-year</li>
<li>Q4: $2.73 billion, +16.2% year-over-year</li>
</ul>
While the report does not share price targets for movie theater stocks, Cinemark Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNK#NYSE">CNK</a>) and IMAX Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IMAX#NYSE">IMAX</a>) are named in the report. AMC Entertainment Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) would be another stock to watch, given the potential increase in domestic 2025 box office revenue.
"While our forecast builds for significant growth, we believe it is below some of the more bullish estimates for $10b-plus which followed strong performance during the holiday period."
The analyst said he remains constructive on the movie theater industry given the rise of the streaming market, specifically increased film output from Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>). The rise of Netflix and streaming platforms has shortened theatrical release windows for movies.
"While these forces have delivered real stress to the ecosystem, with some hindsight, it appears many of the bear theses that existed pre-pandemic were overblown."
The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) is also featured several times in the report, with Karnovsky highlighting upcoming movies like "Zootopia 2," "Snow White," "Lilo &amp; Stitch," "Captain America: Brave New World," "Fantastic Four" and "Avatar: Fire and Ash."
Disney is also highlighted for the early 2026 outlook with movies like "Toy Story 5," a live-action "Moana", "Avengers: Doomsday" and "The Mandalorian &amp; Grogu."
Read Also: <a href="https://www.benzinga.com/24/12/42603589/disney-hits-2-billion-domestic-box-office-wins-top-honors-global-box-office-2025-to-grow-8-to-33b-analyst-says">Disney Hits $2 Billion Domestic Box Office, Earns Top Honors</a>
Goldman Sachs on Movie Theater Stocks: Goldman Sachs analyst Stephen Laszczyk has a domestic box office revenue estimate of $9.4 billion for 2026.
Laszczyk projects a recovery to 82% of 2019 revenue levels, after which earnings would likely remain range-bound.
In the recent report, the analyst highlights IMAX and Cinemark as the two covered stocks in the sector.
The analyst has a Sell rating on Imax with a $16 price target. Despite the sell rating, the analyst sees several scenarios that could provide upside risk to the rating.
"Box office demand could recover more quickly and on a larger scale than expected," Laszczyk said.
The analyst said movie theaters could look to add more Imax screens. A change in China's policy to allow more American blockbusters in the country could also benefit Imax, the analyst added.
"IMAX may benefit from uplifts in ticket prices as studios and exhibitors look to increase revenue."
The analyst also has a Sell rating on Cinemark with a $24 price target.
Similar to Imax, the analyst said there are several scenarios that could provide upside for the movie theater stock.
Along with box office demand recovering faster than expected, the analyst said better food and beverage margins and lower operating expenses could help Cinemark.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/25/01/43017986/warner-bros-discovery-analyst-says-dtc-strength-wont-offset-joker-folie-a-deux-flop-nba-rights-concerns">Warner Bros. Discovery Analyst Says DTC Strength Won&#8217;t Offset &#8216;Joker: Folie A Deux&#8217; Flop, NBA Rights Concerns</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Entertainment

Price Target

Reiteration

Analyst Ratings

IMAX

NFLX

Box Office Set For $9.5 Billion 2025 Comeback As Netflix Reshapes Industry, Analyst Says

BOK Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOKF#NASDAQ">BOKF</a>) reported quarterly earnings of $2.12 per share which beat the analyst consensus estimate of $2.00 by 6 percent. This is a 20.45 percent increase over earnings of $1.76 per share from the same period last year. The company reported quarterly sales of $523.09 million which beat the analyst consensus estimate of $517.35 million by 1.11 percent. This is a 4.29 percent increase over sales of $501.56 million the same period last year.

Earnings

BOKF

BOK Financial Q4 EPS $2.12 Beats $2.00 Estimate, Sales $523.09M Beat $517.35M Estimate

Contracts

EnerSys Completes Contract And Funding Negotiations With US Department of Energy, Securing $199M Award From Office of Manufacturing and Energy Supply Chains

Management

Diana Shipping Announced Maria Dede As Co-Chief Financial Officer For Operations Finance; Ioannis Zafirakis Continues As Co-Chief Financial Officer For Strategic Finance

BOK Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOKF#NASDAQ">BOKF</a>) reported its Q4 earnings results on Friday, January 17, 2025 at 04:03 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
BOK Financial beat estimated earnings by 7.000000000000001%, reporting an EPS of $2.12 versus an estimate of $1.99.
Revenue was up $21.53 million from the same period last year.
<h3>Overview of Past Earnings</h3>
The company beat on EPS by $0.2 in the last quarter, resulting in a 2.0% drop share price change the following day.
Here's a look at BOK Financial's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.98</td>
<td>2.34</td>
<td>1.73</td>
<td>1.75</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.18</td>
<td>2.02</td>
<td>1.91</td>
<td>1.76</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>510.58M</td>
<td>515.37M</td>
<td>480.76M</td>
<td>490.40M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>516.31M</td>
<td>555.73M</td>
<td>455.27M</td>
<td>501.56M</td>
</tr>
</tbody>
</table>

To track all earnings releases for BOK Financial <a href="https://www.benzinga.com/quote/BOKF/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Breakdown: BOK Financial Q4

GBTG

Global Business Travel Group Enters Into Amended Merger Agreement With CWT Holdings; "Drop Dead Date" Changed To March 17, 2025

Nature's Miracle Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMHI#NASDAQ">NMHI</a>) ("Nature's Miracle" or the "Company"), a leader in vertical farming technology and infrastructure, today issued the following statement in response to the delisting notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq"), which indicated that the Nasdaq Hearings Panel has determined to delist the Company's common stock and warrants from Nasdaq due to the Company's failure to comply with minimum shareholder's equity requirement under Nasdaq Listing Rule 5550(b)(1). Trading in the Company's common stock and warrants was suspended effective at the open of business on January 15, 2025. The Company's common stock and warrants continue to trade on OTC Pink Sheet until the Company relists with Nasdaq.
The Company believes it presented a strong plan to the Nasdaq Hearings Panel, including that the Company entered into a Securities Purchase Agreement ("SPA") with an institutional investor on January 10, 2025. The SPA was disclosed to the public on January 13, 2025, along with details of its closing conditions. This announcement, however, led to a 40% decline in the Company's stock price on the same day.

NMHI

Nature's Miracle Faces Nasdaq Delisting Due To Equity Issues; Trades On OTC Pink Sheet; SPA With Institutional Investor Announced; Exploring Mergers And Acquisitions To Strengthen Position

Adams Resources & Energy Faces Two Lawsuits Over Merger Disclosures; Believes Claims Asserted In Litigation Matters Are Without Merit

WIIM

MRNA

Moderna shares are trading higher after the company announced it's receiving ongoing support from the U.S. HHS to accelerate the development of its mRNA-based pandemic influenza vaccines.

SBUX

Starbucks Announces Next Phase Of Back To Starbucks Initiative To Transform Global Support Teams; Focus On Four-Minute Wait, Parental Leave, And Pricing Transparency; Job Cuts Expected By March

Hingham Institution (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIFS#NASDAQ">HIFS</a>) reported quarterly earnings of $2.16 per share. This is a 154.12 percent increase over earnings of $0.85 per share from the same period last year. The company reported $13.44 million in sales this quarter. This is a 43.37 percent increase over sales of $9.38 million the same period last year.

HIFS

Hingham Institution Q4 Adj. EPS $2.16 Up From $0.85 YoY, Sales $13.44M Up From $9.38M YoY

<h3>Gainers</h3>
<ul>
<li>AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) shares moved upwards by 29.7% to $19.5 during Friday's pre-market session. The market value of their outstanding shares is at $593.3 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock rose 25.88% to $0.09. The company's market cap stands at $1.4 million. </li>
<li>Channel Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#AMEX">CHRO</a>) stock increased by 18.74% to $1.14. The company's market cap stands at $6.8 million. </li>
<li>Immuron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRN#NASDAQ">IMRN</a>) stock moved upwards by 18.65% to $2.35. The company's market cap stands at $13.3 million. </li>
<li>Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) stock increased by 14.36% to $1.99. The company's market cap stands at $6.3 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares rose 13.66% to $1.83. The market value of their outstanding shares is at $21.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) shares fell 21.6% to $0.1 during Friday's pre-market session. The market value of their outstanding shares is at $12.7 million. </li>
<li>Scorpius Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SCPX#AMEX">SCPX</a>) stock declined by 17.78% to $0.31. The market value of their outstanding shares is at $1.5 million. </li>
<li>AEON Biopharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AEON#AMEX">AEON</a>) shares declined by 12.29% to $0.15. The market value of their outstanding shares is at $11.9 million. </li>
<li>PureTech Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTC#NASDAQ">PRTC</a>) shares decreased by 7.69% to $16.7. The market value of their outstanding shares is at $399.8 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock fell 7.17% to $3.11. The company's market cap stands at $2.1 million. </li>
<li>QT Imaging Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTI#NASDAQ">QTI</a>) shares declined by 6.88% to $0.49. The company's market cap stands at $10.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEON

ANAB

BLRX

CHRO

GCTK

IMRN

MBRX

PRTC

RNAZ

SCPX

12 Health Care Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Zeo Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZEO#NASDAQ">ZEO</a>) shares increased by 57.7% to $3.69 during Friday's pre-market session. The market value of their outstanding shares is at $51.2 million. </li>
<li>Capital Clean Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCEC#NASDAQ">CCEC</a>) shares increased by 20.21% to $22.0. The company's market cap stands at $1.2 billion. </li>
<li>ATIF Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBAI#NASDAQ">ZBAI</a>) stock moved upwards by 19.98% to $1.8. The market value of their outstanding shares is at $21.4 million. </li>
<li>New Century Logistics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCEW#NASDAQ">NCEW</a>) shares moved upwards by 13.63% to $2.0. The company's market cap stands at $43.0 million. </li>
<li>Nauticus Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) shares moved upwards by 12.14% to $2.49. The market value of their outstanding shares is at $15.9 million. </li>
<li>Caravelle Intl Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCO#NASDAQ">HTCO</a>) stock rose 11.72% to $4.48. The company's market cap stands at $249.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CECO Environmental (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CECO#NASDAQ">CECO</a>) shares fell 11.9% to $28.34 during Friday's pre-market session. The market value of their outstanding shares is at $991.3 million. </li>
<li>Marten Transport (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRTN#NASDAQ">MRTN</a>) stock fell 8.98% to $15.01. The market value of their outstanding shares is at $1.2 billion. </li>
<li>Shimmick (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIM#NASDAQ">SHIM</a>) shares declined by 8.65% to $2.43. The company's market cap stands at $82.1 million. </li>
<li>Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) stock decreased by 8.54% to $14.25. The market value of their outstanding shares is at $1.8 billion. </li>
<li>PS International Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) shares declined by 7.96% to $0.41. The market value of their outstanding shares is at $9.8 million. </li>
<li>JB Hunt Transport Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NASDAQ">JBHT</a>) shares fell 6.25% to $174.58. The company's market cap stands at $17.5 billion. As per the news, the Q4 earnings report came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CCEC

CECO

FLNC

HTCO

JBHT

KITT

MRTN

NCEW

PSIG

SHIM

ZBAI

12 Industrials Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>BTC Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCT#NASDAQ">BTCT</a>) stock increased by 27.7% to $6.08 during Friday's pre-market session. The market value of their outstanding shares is at $31.9 million. </li>
<li>ReAlpha Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRE#NASDAQ">AIRE</a>) stock moved upwards by 20.23% to $2.02. The company's market cap stands at $93.0 million. </li>
<li>Nvni Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNI#NASDAQ">NVNI</a>) shares increased by 16.62% to $1.75. The company's market cap stands at $63.2 million. </li>
<li>Arqit Quantum (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQQ#NASDAQ">ARQQ</a>) stock moved upwards by 15.09% to $32.55. The company's market cap stands at $407.0 million. </li>
<li>Mobix Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOBX#NASDAQ">MOBX</a>) shares increased by 11.38% to $1.37. The market value of their outstanding shares is at $49.0 million. </li>
<li>SEALSQ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) stock increased by 10.91% to $4.83. The company's market cap stands at $379.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>FOXO Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/FOXO#AMEX">FOXO</a>) shares declined by 16.2% to $0.26 during Friday's pre-market session. The company's market cap stands at $6.2 million. </li>
<li>Sobr Safe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) shares fell 9.85% to $0.94. </li>
<li>Enfusion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENFN#NYSE">ENFN</a>) stock decreased by 7.76% to $10.11. The company's market cap stands at $958.1 million. </li>
<li>Quantum (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QMCO#NASDAQ">QMCO</a>) stock declined by 7.19% to $35.8. The company's market cap stands at $173.5 million. </li>
<li>Quantum Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) stock fell 7.17% to $10.1. The market value of their outstanding shares is at $1.3 billion. </li>
<li>Upland Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPLD#NASDAQ">UPLD</a>) shares decreased by 6.72% to $3.72. The company's market cap stands at $102.1 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIRE

ARQQ

BTCT

ENFN

FOXO

LAES

MOBX

NVNI

QMCO

QUBT

SOBR

UPLD

12 Information Technology Stocks Moving In Friday's Pre-Market Session

Moderna Says Ongoing Support From U.S. HHS To Accelerate Development Of mRNA-based Pandemic Influenza Vaccines; $590M Award Funded In Whole Or In Part With Federal Funds From HHS, ASPR, BARDA

Coty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COTY#NYSE">COTY</a>) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Coty, presenting an average target of $9.19, a high estimate of $12.50, and a low estimate of $6.00. Highlighting a 13.87% decrease, the current average has fallen from the previous average price target of $10.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1737147678_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive Coty is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Chris Carey</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$7.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.50</td>
<td>$12.50</td>
</tr>
<tr>
<td>Patty Kanada</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Neutral</td>
<td>$9.00</td>
<td>-</td>
</tr>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Hold</td>
<td>$8.50</td>
<td>-</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$12.50</td>
<td>$14.50</td>
</tr>
<tr>
<td>Olivia Tong</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$11.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$7.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Coty. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Coty compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Coty's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Coty's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/COTY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Coty analyst ratings.</a>
<h2>Delving into Coty's Background</h2>
Coty is a global beauty maker that focuses on fragrance (59% of sales) and color cosmetics (28%), with limited exposure to skincare (5%) and body care (8%). For the fragrance business, Coty licenses luxury and high-end brands including Gucci, Burberry, Hugo Boss, Davidoff, and Calvin Klein, while its consumer cosmetics business focuses on acquired mass brands such as CoverGirl, Max Factor, Rimmel, Sally Hansen, and Bourjois. It also collaborates with social media celebrities Kim Kardashian and Kylie Jenner to launch makeup products bearing their names. By region, Coty generates close to 44% of sales from Europe, 42% from the Americas, and 14% from Asia-Pacific. German investment firm JAB is a controlling shareholder, with a 53% stake.
<h3>Coty: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Coty displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 1.83%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: Coty's net margin excels beyond industry benchmarks, reaching 4.76%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Coty's ROE stands out, surpassing industry averages. With an impressive ROE of 2.02%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Coty's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.65% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Coty's debt-to-equity ratio is below the industry average at 1.04, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

COTY

The Analyst Verdict: Coty In The Eyes Of 8 Experts

Deutsche Bank raised the firm's price target on Sandoz (SDZNY) to CHF 36 from CHF 33 and keeps a Hold rating on the shares. Published first on TheF...

Sandoz price target raised to CHF 36 from CHF 33 at Deutsche Bank

Artisan International Value Fund Q3 2024 Commentary

Artisan Global Discovery Fund Q3 2024 Commentary

Sandoz (SDZNY) announced that the European Commission, or EC, has granted marketing authorization for Afqlir 2 mg vial kit and pre-filled syringe f...

Sandoz receives EC approval for Afqlir

Exane BNP Paribas downgraded Sandoz (SDZNY) to Neutral from Outperform with a CHF 41 price target The firm sees more modest upside in the near-term...

Sandoz downgraded to Neutral from Outperform at Exane BNP Paribas

Sandoz (SDZNY) announced a number of steps to resolve the US Generic Drug Antitrust Class Action Litigation. Following the previously announced set...

Sandoz enters $275M settlement for antitrust litigation

After Intra-Cellular Therapies (ITCI) announced that it has entered into a settlement agreement with Sandoz (SDZNY) resolving patent litigation rel...

RBC buyers of Intra-Cellular after 'more favorable-than-expected' settlement

Intra-Cellular settles Caplyta patent dispute with Sandoz

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Disney (DIS), Fox (FOXA), and Warner B...

Venu Sports JV discontinued, Walgreens reports Q1 beat: Morning Buzz

BofA raised the firm's price target on Intra-Cellular (ITCI) to $118 from $100 and keeps a Buy rating on the shares after the company announced a f...

Intra-Cellular price target raised to $118 from $100 at BofA

ACGL

ACHR

ANCTF

ARGNF

ARGX

ARHS

ARMK

ATRO

AVDL

BABA

BABAF

BCRX

CHYHY

CMPGF

CMPGY

COHR

CRTSF

CWAN

ESTC

FOXA

GALDY

GDERF

GOOG

GOOGL

GRRMF

GRRMY

GWRE

HIMS

HUBB

HXSCF

IRTC

ITCI

JOBY

MPWR

MTSI

MVST

NEOG

NVSEF

NVZMF

NVZMY

ONTO

PLXNF

RYLPF

SDXAY

SDXOF

SPOT

SSNLF

SVNDF

SVNDY

TCOM

TLRY

TREX

TTEK

TTNDF

TTNDY

UNLYF

VEEV

VWDRY

VWSYF

WING

Press Releases

Sandoz reports second-quarter sales and half-year 2024 results

Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position

Introducing Jubbonti® and Wyost®, the first denosumab biosimilars on the Canadian market

Psilocybin's Potentially Revolutionary Ability To Treat Depression Hinges On FDA Approval – AJNA BioSciences Is Standardizing Raw Materials To Meet Guidelines

Sandoz US launches generic paclitaxel in single-dose vial, further expanding US oncology portfolio

Sandoz reports third-quarter and nine-month 2024 sales

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio

Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation

Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference

Comments

Sandoz Group

Sandoz Group (SDZNY) Forecast

Sandoz Group (OTC:SDZNY) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga